Monday, November 12, 2018

4:00 PM to 6:00 PM

  • PRESENTING COMPANY “ICE BREAKER’ SESSION AND COCKTAIL HOUR (BY INVITATION)

    The China Summit Organizing Committee invites the Presenting Company Class of 2018 and International delegates to network with Chinese investors and Biopharma VIPs in an intimate gathering hosted by: 

    • Karen Bernstein, Ph.D., Chairman, BioCentury Inc.   
    • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners  
    • Franck Le Deu, Senior Partner & Head of Greater China Healthcare Practice, McKinsey & Co. 

6:00 PM to 9:00 PM

  • Welcome Reception
    Jing An Shangri-La hotel

    Network with biotech CEOs and investors from China, Asia and the West. 

    Hosted by Pivotal China BioVenture, Nan Fung Life Sciences, BioCentury and BayHelix 

Tuesday, November 13, 2018
  • Innovation and Entrepreneurship at Home AND Abroad

8:00 AM to 9:00 AM

  • REGISTRATION AND BREAKFAST NETWORKING

9:00 AM to 9:10 AM

  • WELCOMING REMARKS
    • David Flores, President & CEO, BioCentury Inc. 
    • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners

9:10 AM to 10:00 AM

  • BLUE RIBBON PANEL: CHALLENGES ON THE ROAD TO GLOBALIZATION

    BayHelix convenes a special Blue Ribbon Panel to debate the mounting obstacles to globalization and their impact on China’s acceleration into the international healthcare ecosystem, its access to international talent and science, and its attractiveness as a destination for Western innovators and investors.

    • Kewen JIN, M.D., Managing Partner, Serica Partners (Session Chair & Moderator)
    • Tao FU, President & Chief Operating Officer, Zai Lab 
    • Nisa Leung, Managing Partner, Qiming Ventures  
    • Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund 
    • Dan Zhang, M.D., Executive Chairman, Fountain Medical Development Ltd. 
    • Lianshan ZHANG, Ph.D., SVP and President, Global R&D, Jiangsu Hengrui Medicine Co. 

10:00 AM to 10:30 AM

  • MORNING NETWORKING BREAK

10:10 AM to 11:30 AM

  • PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 2)

    Hosted by the Korea Drug Development Fund (KDDF), Kinhalo Ventures Korea, BioCentury and BayHelix 

    • Tae-erk Kim, Chief Business Officer, KDDF (emcee) 

10:30 AM to 11:00 AM

  • BLUE RIBBON RAPPORTEUR SESSION: DOMESTIC BIOPHARMA

    In a Fireside Chat, the leader of the innovative domestic biopharma industry association responds to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization. 

    • Ruilin SONG, Executive President, PhIRDA (China Pharmaceutical Innovation and Research Development Association) (Session Chair) 
    • Victor Shi, Ph.D., Chairman, BayHelix & Managing Partner, Serica Partners (Moderator)

11:00 AM to 11:30 AM

  • BLUE RIBBON RAPPORTEUR SESSION: INTERNATIONAL BIOPHARMA

    International biopharma leaders respond to points raised during the China Summit’s Blue Ribbon Panel: Challenges on the Road to Globalization.  

    • David Flores, President & CEO, BioCentury Inc. (Session Chair & Moderator) 
    • Steve Bates, CEO, BioIndustry Association (BIA) 
    • Joseph Damond, EVP, International Affairs, Biotechnology Innovation Organization (BIO) 
    • Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee) 
    • Hyunsang MUK, President & CEO, Korea Drug Development Fund (KDDF) 

11:30 AM to 12:10 PM

  • PRESENTING COMPANIES TRACK (SESSION 3)

11:30 AM to 12:20 PM

  • CHINA’S GLOBALIZATION CHALLENGE: INCUBATING BIOTECHS

    Every nation recognizes the importance of incubating life science start-ups. But only a few succeed. The challenges are even higher for China as it races to do so in a rapidly changing landscape. What must it do to create a robust incubator ecosystem that serves both domestic and international priorities simultaneously?  

    • Jimmy Wei, Ph.D., Managing Partner, Pivotal bioVenture Partners China (Session Chair & Moderator)  
    • Laura Benjamin, Ph.D., Founder & CEO, Oncologie Ltd. 
    • Da LIU, Managing Director, CR-CP Life Science Fund 
    • Tyrone Mao, Senior Director, Scientific Innovation, JLABS@Shanghai 
    • Karoly Nikolich, Ph.D., CEO & Chairman, Alkahest Inc. 
    • Antoine Papiernik, Managing Partner, Sofinnova Partners 

12:20 PM to 1:20 PM

  • LUNCH AND NETWORKING WITH PRESENTING COMPANIES

    Meet with the China Healthcare Summit Presenting Company Class of 2018 and fellow delegates in this special boxed lunch networking session.

1:20 PM to 3:00 PM

  • PRESENTING COMPANIES: U.K. BIOTECH TRACK (SESSION 2)

    Hosted by the BioIndustry Association (BIA), BioCentury and BayHelix 

    • Steve Bates, CEO, BIA (emcee) 

1:20 PM to 2:10 PM

  • CHINA’S GLOBALIZATION CHALLENGE: DELIVERING RARE DISEASE SOLUTIONS AT HOME AND ABROAD?

    By issuing its first national rare disease list, China has opened the door to a huge untapped market. But the pathway from clinic to reimbursement still must be built. As the market evolves, what must domestic and Western innovators do to deliver hope to patients in China? And how can Chinese biotechs make their presence felt in the global rare disease landscape?  

    • James Xue, Ph.D., Chairman & CEO, Canbridge Life Sciences Ltd. (Session Chair & Moderator) 
    • Kevin Huang, Ph.D., Director, China Rare Disease Development Center 
    • Thaminda Ramanayake, Director, Business Development, BioMarin Pharmaceuticals 
    • Richard Yang, Founder & CEO, Reflection Biotechnologies

2:10 PM to 3:10 PM

  • CHINA’S GLOBALIZATION CHALLENGE: LEVERAGING ITS AI FUTURE

    China’s commitment to population health, artificial intelligence and machine learning give it the wherewithal to make great strides in applying technology to domestic healthcare. Can it also create digital health powerhouses on a global scale?   

    • Stanley Li, M.D., Founder, DXY (Session Chair) 
    • Andrea de Souza, Senior Director, Informatics, Eli Lilly and Company (Moderator) 
    • Pek Lum, Ph.D., CEO & Founder, Auransa Inc. 
    • Alex Zhavoronkov, Ph.D., Co-Founder & CEO, Insilico Medicine Inc.

3:00 PM to 6:00 PM

  • PRESENTING COMPANIES: CHINA BIOTECH TRACK (SESSION 5)

    Hosted by BeiGene Ltd., BioCentury and BayHelix 

    • Guillaume Vignon, Ph.D., SVP, Business Development, BeiGene Ltd. (emcee) 

3:10 PM to 3:40 PM

  • AFTERNOON NETWORKING BREAK

3:40 PM to 4:30 PM

  • CHINA’S GLOBALIZATION CHALLENGE: BUILDING THE ACADEMIC-BIOTECH NEXUS

    Global innovation has been built on the shoulders of academic institutions and biotech companies, which continue to convert new science into breakthrough treatments. The challenge is to create a clear path for assets and IP from the university into the hands of entrepreneurs. What must China’s universities, innovators and investors do to build an internationally recognized innovation engine?  

    • Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair & Moderator) 
    • Deborah Chen, Ph.D., Head of Business Development & Licensing, Drug Discovery and Development, A*STAR, Singapore 
    • James Huang, Managing Partner, KPCB China, and Managing Partner, Panacea Venture 
    • Liming SHAO, Ph.D., Professor and Director, Shanghai Center for iDrug Discovery & Development, School of Pharmacy, Fudan University 
    • Litao ZHANG, Ph.D., VP, Leads Discovery & Optimization, Bristol-Myers Squibb Co. 
    • Nick Zhang, Ph.D., Chairman & CEO, Qiagen Suzhou Translational Medicine Co. Ltd. 

4:30 PM to 5:30 PM

  • WHITHER INNOVATION IN CHINA?

    In the China Summit’s 3rd Annual Heads of Research Roundtable, R&D heads and “scientist-CEOs” from China and Abroad analyze how far China has come and what it now must accomplish to meet international expectations. 

    • Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec (Session Chair & Moderator) 
    • Ruth Gimeno, Ph.D., VP, Diabetes Research & Clinical Investigation, Eli Lilly and Co. 
    • Zhi HONG, Ph.D., Co-Founder, President & CEO, Brii Biosciences 
    • Xiayang QIU, Ph.D., Founder, CEO & CSO, Regor Therapeutics Inc. 
    • Doug Williams, Ph.D., President & CEO, Codiak BioSciences 

6:00 PM to 10:00 PM

  • 5TH ANNIVERSARY GALA DINNER AND AFTER PARTY

    Celebrate the 5th anniversary of the BioCentury-BayHelix China Healthcare Summit with fellow delegates and Shanghai life sciences leaders at our Gala Dinner and After Party. 

    Hosted by C-Bridge Capital, H.C. Wainwright, BioCentury and BayHelix 

Wednesday, November 14, 2018
  • Theme: Managing for Domestic AND Global Impact

8:00 AM to 9:00 AM

  • PRESENTING COMPANIES TRACK (SESSION 6) AND BREAKFAST NETWORKING

8:50 AM to 9:00 AM

  • WELCOMING REMARKS

9:00 AM to 9:40 AM

  • KEYNOTE: THINKING BIG ABOUT CHINA’S HEALTHCARE ECOSYSTEM

    China's ambitious population health goals require brave initiatives, innovative partnerships and the skills of players from inside and outside the country. This opening keynote sets the stage for the day's discussion about how globally facing companies can work across borders and across technologies to create a healthy China.  

    • Leon Wang, EVP, International, AstraZeneca

9:40 AM to 10:40 AM

  • THE BRIDGE TO INNOVATION: LOOKING ACROSS TO 2025

    Insights Partner McKinsey & Co. delivers the key findings from its 5th exclusive China Healthcare Summit Report for conference delegates, reflecting on what must be done to complete the Bridge to Innovation and where it could lead by 2025.  

    • Fangning ZHANG, Partner, McKinsey & Co.

10:40 AM to 11:00 AM

  • MORNING NETWORKING BREAK

10:40 AM to 12:00 PM

  • PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 5)

    Hosted by the Korea Drug Development Fund (KDDF), Kinhalo Ventures Korea, BioCentury and BayHelix 

    • Tae-erk Kim, Chief Business Officer, KDDF (emcee)

11:00 AM to 12:10 PM

  • VIEW FROM THE TOP: BIOPHARMA GM PERSPECTIVES

    In their 5th annual dialogue at the China Summit, general managers from the MNCs and China's emerging class of multinational biotechs share their formulas for building a profitable product mix as the market access landscape undergoes its next round of reforms. 

    • Aamir Malik, Senior Partner & Co-Leader, Global Pharmaceuticals and Medical Products Practice, McKinsey & Co. (Session Chair & Moderator) 
    • Rogier Janssens, General Manager, China, Merck Biopharma China 
    • Dirk Van Niekerk, General Manager, China, Boehringer Ingelheim 
    • Thomas Willemsen, Chairman, GSK China Investment Co. Ltd. 
    • Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd. 

12:10 PM to 1:40 PM

  • 9TH ANNUAL BAYHELIX AWARDS LUNCH BANQUET

    BayHelix again celebrates outstanding individuals and companies for their achievements and contributions to China’s healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year. 

    • Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners (emcee) 

1:40 PM to 2:30 PM

  • CHINA’S GLOBALIZATION CHALLENGE: NEW MODALITIES AND ADVANCED MANUFACTURING

    In the race to lead in new therapeutic modalities like CAR T and other cell therapies, all roads run through manufacturing. But if global prowess in manufacturing is necessary, it is not sufficient. As China creates its beachhead in manufacturing, what more must it do to deliver these treatments to patients at home and abroad? 

    • James Li, M.D., CEO, JW Therapeutics Inc. 
    • David Oxley, SVP, Business Development & Licensing, Mesoblast Ltd. 
    • BG Rhee, CEO, SCM Life Sciences 

1:50 PM to 4:10 PM

  • PRESENTING COMPANIES GLOBAL BIOTECH TRACK 2 (SESSION 8)

    Hosted by Zai Lab Ltd., BioCentury and BayHelix 

    • Tao FU, President & Chief Operating Officer, Zai Lab Ltd. (emcee)

2:30 PM to 3:20 PM

  • READY TO CROSS THE BRIDGE?

    As market pressures grow at home, Chinese pharmas are facing the imperative to globalize. Here’s how they plan to do it. Will they compete for deals with China’s internationally focused biotechs? And what does it mean for cross-border dealmakers from the West? 

    • Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital (Session Chair & Moderator) 
    • Sean Cao, Ph.D., President & Interim CEO, Everest Medicines and Managing Director, C-Bridge Capital 
    • Ivor Royston, M.D., CEO, Viracta Therapeutics Inc. 
    • Donald Wyatt, VP, Business Development, 3SBio Inc.

3:20 PM to 3:40 PM

  • AFTERNOON NETWORKING BREAK

3:40 PM to 4:30 PM

  • CAPITAL MARKETS SHOWCASE: HOT MARKETS TODAY … WHAT ABOUT TOMORROW?

    2018 is chasing records for global financing for public and private biotechs, with IPO news dominating in both Hong Kong and the U.S. But what will be the story in 2019? And how should China’s biotechs be building a strategy for accessing the capital markets over the long-term, not just when the market is hot? 

    • Mengyu YU, Partner, Sidley Austin (Session Chair & Moderator) 
    • Kenny Lam, Managing Director & Head of Healthcare Asia, Global Banking, HSBC 
    • George Lin, EVP & CFO, Hua Medicine 
    • Ziyi CHEN, China Healthcare Research Analyst, Goldman Sachs 
    • Jonathan Wang, Ph.D., Co-founder & Senior Managing Director, OrbiMed Asia 

4:30 PM to 5:00 PM

  • INTERNATIONAL PERSPECTIVES: VOICES FROM ABROAD

    In the Summit's capstone rapporteur session, biotech leaders from the U.S., Europe and Asia reflect on what they have learned about China's prospects for leadership at home and abroad in innovation and entrepreneurship. 

    • Simone Fishburn, Ph.D., Executive Editor, BioCentury (Session Chair & Moderator) 
    • Jie D'Elia, Ph.D., Executive Director, Business Development, Bristol-Myers Squibb Co. 

5:00 PM

  • CLOSING REMARKS